Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
|
| gptkbp:activeIngredient |
gptkb:methadone
|
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:brandFor |
gptkb:methadone
|
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:drugClass |
opioid
|
| gptkbp:form |
gptkb:tablet
oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Dolophine
|
| gptkbp:marketedAs |
Roxane Laboratories
|
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:usedFor |
pain management
opioid dependence |
| gptkbp:bfsParent |
gptkb:methadone
gptkb:Methadone |
| gptkbp:bfsLayer |
6
|